Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
272 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Please note that only the first 5 legal search words are being processed.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
001696-C
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
Recruitment has not started
3-120 Years
NCI
Malignant Neoplasm Peripheral Nerve
20-C-0023
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid Tumors
Participants currently recruited/enrolled
12-120 Years
NCI
Malignant Neoplasm Peripheral Nerve
19-C-0016
Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
Participants currently recruited/enrolled
0-125 Years
NCI
Malignant Neoplasm Peripheral Nerve
001715-C
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associ
Participants currently recruited/enrolled
12-120 Years
NCI
Neoplasm Nerve
001678-AT
Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals with Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Gene
Recruitment has not started
18-100 Years
NCCIH
Peripheral Nerve
001608-N
Pre-operative vs. Post-operative Stereotactic Radiosurgery for Operative Metastatic Brain Tumors
Participants currently recruited/enrolled
18-99 Years
NINDS
Malignant Neoplasm
001549-C
Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects with BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Participants currently recruited/enrolled
18-120 Years
NCI
Malignant Peripheral
001544-C
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with Entinostat and Nivolumab as Adjuvant Therapy following Chemoradiation Therapy with or without Surgery for Locally Advanced Esophageal Cancer
Clinical hold/Recruitment or enrollment suspended
18-120 Years
NCI
Neoplasm Peripheral
000697-H
U01 Cooperative Assessment of Late Effects for SCD Curative Therapies (COALESCE)
Participants currently recruited/enrolled
18-65 Years
NHLBI
Malignant Neoplasm
000625-N
Investigational use of Neuromuscular Ultrasound
Participants currently recruited/enrolled
18-110 Years
NINDS
Peripheral Nerve
000473-C
A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm Peripheral
000464-H
Evaluation of Clonal Hematopoiesis in Patients with Sickle Cell Disease Receiving Curative Therapies
Enrolling by Invitation
4-125 Years
NHLBI
Malignant Neoplasm
000305-C
Exploratory Phase II Study of LAnreotide in Unresectable or Metastatic Pheochromocytoma / PARAganglioma
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm Nerve
21-C-0015
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma
Participants currently recruited/enrolled
18-125 Years
NCI
Malignant Peripheral
20-C-0121
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm Peripheral
20-C-0041
Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Enrolling by Invitation
1-125 Years
NCI
Neoplasm Peripheral
19-C-0061
A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Completed Study; data analyses ongoing
12-125 Years
NCI
Malignant Nerve
19-C-0061
A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Completed Study; data analyses ongoing
12-125 Years
NCI
Malignant Peripheral
19-C-0061
A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Completed Study; data analyses ongoing
12-125 Years
NCI
Peripheral Nerve
17-C-0048
Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas
Completed Study; data analyses ongoing
18-73 Years
NCI
Malignant Peripheral
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm Peripheral
16-C-0034
A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
Completed Study; data analyses ongoing
18-125 Years
NCI
Malignant Neoplasm
14-C-0163
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis
Completed Study; data analyses ongoing
10-125 Years
NCI
Malignant Nerve
14-C-0163
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis
Completed Study; data analyses ongoing
10-125 Years
NCI
Malignant Peripheral
14-C-0163
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis
Completed Study; data analyses ongoing
10-125 Years
NCI
Peripheral Nerve
13-C-0202
Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing Cancers
Participants currently recruited/enrolled
2-125 Years
NCI
Malignant Neoplasm
11-C-0190
Collection of Tissue Blocks or Slides from Patients with Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Malignant Neoplasm
10-C-0056
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Malignant Neoplasm
09-C-0242
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Participants currently recruited/enrolled
4-125 Years
NCI
Malignant Neoplasm
08-N-0044
A Prospective Natural History Study of Patients with Neurofibromatosis Type 2 (NF2).
Participants currently recruited/enrolled
8-75 Years
NINDS
Peripheral Nerve
08-C-0130
A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
Completed Study; data analyses ongoing
0-21 Years
NCI
Peripheral Nerve
08-C-0079
Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1
No longer recruiting/follow-up only
0-125 Years
NCI
Malignant Nerve
08-C-0079
Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1
No longer recruiting/follow-up only
0-125 Years
NCI
Malignant Peripheral
08-C-0079
Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1
No longer recruiting/follow-up only
0-125 Years
NCI
Peripheral Nerve
07-N-0122
Modulation of Motor Function by Stimulation of the Central and Peripheral Nervous System
Completed Study; data analyses ongoing
18-125 Years
NINDS
Peripheral Nerve
02-I-0286
Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome
Participants currently recruited/enrolled
2-125 Years
NIAID
Neoplasm Peripheral
00-N-0043
Clinical and Molecular Manifestations of Inherited Neurological Disorders
Participants currently recruited/enrolled
2-120 Years
NINDS
Peripheral Nerve
00-CH-0160
Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical Tissue
Completed Study; data analyses ongoing
3-70 Years
NICHD
Malignant Neoplasm
97-C-0147
Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Diseases
Participants currently recruited/enrolled
2-125 Years
NCI
Malignant Neoplasm
94-I-0079
Eosinophil Activation and Function in Parasitic Infections and Other Conditions with Increased Tissue or Peripheral Blood Eosinophilia in Humans
Participants currently recruited/enrolled
1-100 Years
NIAID
Peripheral Nerve
002056-C
Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
Recruitment has not started
18-120 Years
NCI
Neoplasm
001961-C
A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001924-C
A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors
Recruitment has not started
18-120 Years
NCI
Neoplasm
001920-C
A ComboMATCH Treatment Trial: FOLFOX In Combination With Binimetinib As 2nd Line Therapy For Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001874-M
Natural History of Depression, Bipolar Disorder and Suicide Risk
Recruitment has not started
18-120 Years
NIMH
Peripheral
001837-C
A Phase I Study to Establish the Feasibility of Enolen(TM) for the Local Delivery of Enzalutamide in Patients with Prostate Cancer
Participants currently recruited/enrolled
21-120 Years
NCI
Neoplasm
001826-C
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems using Pupillometry in Participants with Neurofibromatosis Type 1 (NF1)
Recruitment has not started
1-120 Years
NCI
Nerve
001784-C
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Recruitment has not started
18-120 Years
NCI
Neoplasm
001783-C
An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cel
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001778-C
A Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001776-C
A Phase 1 Dose Escalation and Expansion Study of GIGA-564, a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody, in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001732-C
A Phase 1 Study of the Polymerase Theta (POL-Theta) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid Tumors
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001695-C
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (anti-VISTA) as Monotherapy and in Combination with Cemiplimab in Patients with Advanced Solid Tumors
Recruitment has not started
18-120 Years
NCI
Neoplasm
001657-C
Phase 1 Umbrella Trial of Erlotinib In Combination with Select Tyrosine Kinase Inhibitors In Adult Patients with Advanced Solid Tumors
Recruitment has not started
18-120 Years
NCI
Neoplasm
001636-CC
A Pilot Study of a Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
Participants currently recruited/enrolled
18-100 Years
CC
Neoplasm
001625-HG
Prospective Study of the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders
Participants currently recruited/enrolled
0-100 Years
NHGRI
Nerve
001619-H
A Phase I Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease
Recruitment has not started
18-65 Years
NHLBI
Nerve
001572-C
A Phase II Study of Bevacizumab in Adults with Recurrent Respiratory Papillomatosis (RRP)
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001569-C
A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
Recruitment has not started
18-100 Years
NCI
Neoplasm
001567-C
Observational Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy
Participants currently recruited/enrolled
35-120 Years
NCI
Neoplasm
001560-DC
NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
Participants currently recruited/enrolled
3-99 Years
NIDCD
Neoplasm
001554-C
Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Recruitment has not started
12-120 Years
NCI
Neoplasm
001552-C
Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors
Participants currently recruited/enrolled
18-120 Years
NCI
Malignant
001547-C
A First-in-Human Phase I Trial with Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
001534-C
Phase I/II Trial of PLX038 in Primary Central Nervous System Tumors containing MYC or MYCN Amplifications
Participants currently recruited/enrolled
18-120 Years
NCI
Malignant
001519-N
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy: A Pilot Study
Participants currently recruited/enrolled
18-120 Years
NINDS
Nerve
001517-H
Single Patient Study of JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease
Participants currently recruited/enrolled
18-100 Years
NHLBI
Nerve
001505-N
A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, First In-Patient Study of AJ201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults With Spinal and Bulbar Muscular Atrophy (SBMA)
Participants currently recruited/enrolled
18-120 Years
NINDS
Nerve
001109-C
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Participants currently recruited/enrolled
8-125 Years
NCI
Malignant
000954-C
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing Cancer
No longer recruiting/follow-up only
18-120 Years
NCI
Neoplasm
000908-DK
Peripheral Blood and Urine Immune Cell Phenotyping in Membranous Nephropathy using FACS and Single Cell RNA-seq
Participants currently recruited/enrolled
18-125 Years
NIDDK
Peripheral
000865-N
Natural History Protocol for Movement Disorders
Participants currently recruited/enrolled
2-100 Years
NINDS
Nerve
000780-D
A Phase 2 Study of Denosumab for Prevention of Skeletal Disease Progression in Children with Fibrous Dysplasia
Participants currently recruited/enrolled
4-14 Years
NIDCR
Nerve
000767-CC
Phase I Open Label Clinical Trial Using Resiniferatoxin, A Non-Opioid Medication, For the Management of Refractory Morton's Neuroma Pain
Participants currently recruited/enrolled
18-125 Years
CC
Nerve
000732-C
A Long-Term Follow-Up Study of Patients Who Received VOR33
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000696-C
A Phase III, Multicenter, International Study with a Parallel, Randomized, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF1 who have Symptomatic, Inoperable Plexiform Neurofibr
No longer recruiting/follow-up only
18-120 Years
NCI
Nerve
000678-C
Rare Tumors and Cancer Predisposition in Individuals and Families
Participants currently recruited/enrolled
0-125 Years
NCI
Neoplasm
000666-C
A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Participants currently recruited/enrolled
18-100 Years
NCI
Neoplasm
000661-C
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
Participants currently recruited/enrolled
0-120 Years
NCI
Neoplasm
000633-C
Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Peripheral
000613-C
Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood St
Participants currently recruited/enrolled
12-125 Years
NCI
Peripheral
000611-C
A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
000580-C
A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2(alpha) Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinom
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000560-N
Data Collection of Standard Care of Patients in the EMG Section
Participants currently recruited/enrolled
18-110 Years
NINDS
Nerve
000491-C
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000489-C
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
Participants currently recruited/enrolled
12-120 Years
NCI
Neoplasm
000417-CC
Characterization of the Nociception Phenotype in Individuals with Intellectual Disability
Participants currently recruited/enrolled
8-30 Years
CC
Nerve
000359-C
Phase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignancies
Participants currently recruited/enrolled
12-85 Years
NCI
Neoplasm
000356-C
A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
000317-C
A Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-120 Years
NCI
Peripheral
000307-C
Phase II Study Evaluating the Efficacy of M9241 in Combination with Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects with Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000302-C
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000274-C
Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Clinical hold/Recruitment or enrollment suspended
18-125 Years
NCI
Neoplasm
000237-C
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000123-CC
Evaluation of Atherosclerotic Plaques in Abdominal CT Studies
No longer recruiting/follow-up only
30-90 Years
CC
Neoplasm
000103-C
A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
000094-N
An Observational Study of Neurologic Function After COVID -19 Infection
Completed Study; data analyses ongoing
18-125 Years
NINDS
Nerve
000081-C
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
Completed Study; data analyses ongoing
2-125 Years
NCI
Malignant
000067-C
Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy
Completed Study; data analyses ongoing
2-125 Years
NCI
Neoplasm
000059-C
Phase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant Mesothelioma
Completed Study; data analyses ongoing
18-120 Years
NCI
Malignant
000030-C
Phase 2 Study of Bintrafusp alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
22-C-0005
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
21-M-0018
Characterization of an Optically Pumped Magnetometer (OPM) Magnetoencephalography (MEG) Array
Participants currently recruited/enrolled
18-65 Years
NIMH
Nerve
21-C-0032
GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure
Participants currently recruited/enrolled
0-40 Years
NCI
Neoplasm
21-C-0024
A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
No longer recruiting/follow-up only
18-125 Years
NCI
Malignant
21-C-0022
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR(TM) T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Participants currently recruited/enrolled
10-75 Years
NCI
Neoplasm
21-C-0021
SARC037: A Phase I Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
No longer recruiting/follow-up only
6-125 Years
NCI
Malignant
21-C-0011
A Phase 0/I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical Neurofibromas
Participants currently recruited/enrolled
12-125 Years
NCI
Nerve
21-C-0006
Phase II Study Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
21-C-0001
A Phase I/II Study of M9241 with Docetaxel and Abiraterone in Adults with Metastatic Castration Sensitive and M9241 with Docetaxel in Castration Resistant Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
20-N-0077
Study of Volition: Behavioral analysis and Clinical Neurophysiological Analysis
Completed Study; data analyses ongoing
25-45 Years
NINDS
Nerve
20-C-0161
Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Participants currently recruited/enrolled
6-125 Years
NCI
Neoplasm
20-C-0150
Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
20-C-0130
A Feasibility Study Investigating the Use of Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain
Completed Study; data analyses ongoing
12-120 Years
NCI
Neoplasm
20-C-0127
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
Peripheral
20-C-0069
A First-In-Human Phase I Single-Agent Dose-Escalation and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
20-C-0051
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Enrolling by Invitation
18-120 Years
NCI
Neoplasm
20-C-0028
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Participants currently recruited/enrolled
3-35 Years
NCI
Neoplasm
20-C-0024
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.
Completed Study; data analyses ongoing
18-120 Years
NCI
Neoplasm
20-C-0022
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
20-C-0012
A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
19-M-0073
Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)
Participants currently recruited/enrolled
22-70 Years
NIMH
Nerve
19-I-0080
Haploidentical Transplant for Patients with Chronic Granulomatous Disease (CGD) using Alemtuzumab, Busulfan and TBI with Post-Transplant Cyclophosphamide
Participants currently recruited/enrolled
4-65 Years
NIAID
Peripheral
19-HG-0101
A Phase 1/2 Study of Intravenous Gene Transfer with an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis
Participants currently recruited/enrolled
0-12 Years
NHGRI
Nerve
19-H-0118
Repeat Peripheral Blood Stem Cell Transplantation for Patients with Sickle Cell Disease or Beta-Thalassemia and Falling Donor Myeloid Chimerism Levels
Participants currently recruited/enrolled
2-80 Years
NHLBI
Peripheral
19-C-0138
Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
19-C-0128
A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with Tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
19-C-0117
A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing Cancer
No longer recruiting/follow-up only
18-120 Years
NCI
Neoplasm
19-C-0112
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Participants currently recruited/enrolled
12-120 Years
NCI
Neoplasm
19-C-0096
Studying the Biology of IDH-mutant Gliomas via Longitudinal Observation of 2-Hydroxyglutarate (2-HG) Using MR Spectroscopy
Participants currently recruited/enrolled
18-125 Years
NCI
Malignant
19-C-0085
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell Lymphoma
Participants currently recruited/enrolled
12-120 Years
NCI
Peripheral
19-C-0046
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
No longer recruiting/follow-up only
18-125 Years
NCI
Peripheral
19-C-0040
Natural History Study of Men at High Genetic Risk for Prostate Cancer
Participants currently recruited/enrolled
30-75 Years
NCI
Neoplasm
19-C-0017
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Participants currently recruited/enrolled
18-72 Years
NCI
Peripheral
19-C-0006
Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype
Participants currently recruited/enrolled
18-125 Years
NCI
Malignant
19-AT-0089
Sensory Afferents for Deep Pressure Sensation
Completed Study; data analyses ongoing
18-50 Years
NCCIH
Nerve
18-N-0133
Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery
Participants currently recruited/enrolled
18-85 Years
NINDS
Neoplasm
18-H-0090
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH using Peripheral Blood Stem Cells and post-transplant Cyclophosphamide for GVHD Prophylaxis
Participants currently recruited/enrolled
4-75 Years
NHLBI
Peripheral
18-DC-0051
Biospecimen Procurement for the Study of Head and Neck Disorders
Participants currently recruited/enrolled
3-120 Years
NCI
Neoplasm
18-CH-0031
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Clinical hold/Recruitment or enrollment suspended
7-70 Years
NIDDK
Neoplasm
18-C-0102
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (cNF)
Completed Study; data analyses ongoing
18-125 Years
NCI
Nerve
18-C-0078
A Phase I/II Study of Immunotherapy Combination BN-Brachyury vaccine, M7824, N-803 and Epacadostat (QuEST1)
No longer recruiting/follow-up only
18-120 Years
NCI
Neoplasm
18-C-0058
A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
18-C-0028
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
18-C-0014
Phase I Trial of 5-aza-4'-thio-2'-Deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
18-C-0008
Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
17-N-0131
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Participants currently recruited/enrolled
18-125 Years
NINDS
Nerve
17-N-0035
Clinical and Physiological Studies of Tremor Syndromes
Completed Study; data analyses ongoing
18-125 Years
NINDS
Nerve
17-M-0147
Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes
Participants currently recruited/enrolled
18-75 Years
NIMH
Nerve
17-H-0124
Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using Plerixafor
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Peripheral
17-H-0069
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
No longer recruiting/follow-up only
2-100 Years
NHLBI
Peripheral
17-C-0158
A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer Patients
Enrolling by Invitation
18-120 Years
NCI
Neoplasm
17-C-0157
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
17-C-0156
Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer Institute
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
17-C-0153
Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer after Prior Radiotherapy
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
17-C-0140
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Completed Study; data analyses ongoing
18-99 Years
NCI
Malignant
17-C-0113
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Participants currently recruited/enrolled
18-72 Years
NCI
Peripheral
17-C-0109
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Enrolling by Invitation
18-125 Years
NCI
Neoplasm
17-C-0100
Collection of Malignant Ascites, Pleural Fluid and Blood from Patients with Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Malignant
17-C-0092
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
17-C-0089
Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate Cancer
Enrolling by Invitation
18-125 Years
NCI
Neoplasm
17-C-0087
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
17-C-0044
Prospective Evaluation and Molecular Profiling in Patients with Gastric Tumors
Participants currently recruited/enrolled
2-125 Years
NCI
Neoplasm
17-C-0043
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
Participants currently recruited/enrolled
2-125 Years
NCI
Neoplasm
17-C-0034
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Completed Study; data analyses ongoing
18-125 Years
NCI
Malignant
16-N-0166
Deep Brain Stimulation Surgery for Treatment of Focal Hand Dystonia
No longer recruiting/follow-up only
22-100 Years
NINDS
Nerve
16-N-0114
The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study
Participants currently recruited/enrolled
18-120 Years
NINDS
Nerve
16-N-0041
Tumor Related Epilepsy
Participants currently recruited/enrolled
8-99 Years
NINDS
Neoplasm
16-I-0032
High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease
No longer recruiting/follow-up only
4-65 Years
NIAID
Peripheral
16-CC-0098
Pilot Study of Ultrasound Guided Focal Thermal Ablation of Prostate Cancer
Clinical hold/Recruitment or enrollment suspended
18-100 Years
CC
Neoplasm
16-CC-0049
A Phase II Study Using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment with Transarterial Embolization (TAE) Alone or Combined with Thermal Ablation
Completed Study; data analyses ongoing
18-100 Years
CC
Neoplasm
16-C-0171
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
16-C-0154
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
16-C-0151
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
16-C-0138
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy
Participants currently recruited/enrolled
18-120 Years
NCI
Peripheral
16-C-0131
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing Cancers
Participants currently recruited/enrolled
18-72 Years
NCI
Peripheral
16-C-0128
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
16-C-0121
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
16-C-0107
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
16-C-0097
Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma
Completed Study; data analyses ongoing
2-21 Years
NCI
Neoplasm
16-C-0092
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
16-C-0087
Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination with Cisplatin in Patients with Refractory Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
16-C-0048
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
16-C-0043
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
No longer recruiting/follow-up only
18-125 Years
NCI
Nerve
16-C-0011
A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Malignant
16-AT-0136
Effects of External Ear Stimulation on Pain Perception and Mood
Participants currently recruited/enrolled
18-50 Years
NCCIH
Nerve
15-N-0126
HERV-K Suppression using Antiretroviral Therapy in Volunteers with Amyotrophic Lateral Sclerosis (ALS)
Completed Study; data analyses ongoing
18-125 Years
NINDS
Nerve
15-N-0125
Natural History Study of Inflammatory and Infectious Diseases of the Nervous System
Participants currently recruited/enrolled
2-110 Years
NINDS
Nerve
15-N-0073
A Phase I Study of Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy
Participants currently recruited/enrolled
3-99 Years
NINDS
Nerve
15-H-0172
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
No longer recruiting/follow-up only
18-125 Years
NHLBI
Neoplasm
15-H-0016
A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response.
No longer recruiting/follow-up only
18-125 Years
NHLBI
Peripheral
15-C-0200
Molecular Analysis for Therapy Choice (MATCH) (EAY131)
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
15-C-0160
A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
15-C-0150
A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
15-C-0145
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
15-C-0116
Phase I Trial of 4'-thio-2'-deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
Clinical hold/Recruitment or enrollment suspended
18-120 Years
NCI
Neoplasm
15-C-0086
Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients with Refractory Solid Tumors
Participants currently recruited/enrolled
12-120 Years
NCI
Neoplasm
15-C-0078
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
No longer recruiting/follow-up only
18-65 Years
NCI
Peripheral
15-C-0076
A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
15-C-0075
A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
15-C-0019
The Impact of Ras/MAPK Signaling Pathway-Targeted Therapies on Neurocognitive Functioning in Individuals with NF1
Completed Study; data analyses ongoing
4-99 Years
NCI
Nerve
15-AR-0165
Study of the Natural History, Pathogenesis and Outcome of Melorheostosis - a Rare Osteosclerotic Disease
Participants currently recruited/enrolled
18-90 Years
NIAMS
Nerve
15-AR-0060
The Role of PPAR-gamma Agonists in immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Completed Study; data analyses ongoing
18-99 Years
NIAMS
Peripheral
14-I-0020
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Participants currently recruited/enrolled
18-65 Years
NIAID
Peripheral
14-HG-0071
Clinical and Basic Investigations into Known and Suspected Congenital Disorders of Glycosylation
Participants currently recruited/enrolled
1-80 Years
NHGRI
Nerve
14-HG-0055
Study on Moebius Syndrome and Other Congenital Facial Weakness Disorders
Completed Study; data analyses ongoing
2-80 Years
NHGRI
Nerve
14-HG-0048
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)
Completed Study; data analyses ongoing
21-65 Years
NHGRI
Peripheral
14-H-0077
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals with Higher Risk of Transplant Failure
No longer recruiting/follow-up only
4-80 Years
NHLBI
Peripheral
14-C-0161
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Participants currently recruited/enrolled
18-120 Years
NCI
Neoplasm
14-C-0128
Collection of Pharmacokinetic and Probe Substrate Samples from Participants with Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
Enrolling by Invitation
2-125 Years
NCI
Neoplasm
14-C-0004
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Malignant
14-C-0001
Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Completed Study; data analyses ongoing
18-125 Years
NCI
Malignant
13-N-0165
Electrical Impedance Myography: Natural History Studies in Neuromuscular Disorders and Healthy Volunteers
Participants currently recruited/enrolled
2-110 Years
NINDS
Nerve
13-N-0140
Cerebrospinal Fluid Collection and Repository Storage
Participants currently recruited/enrolled
2-110 Years
NINDS
Nerve
13-C-0176
Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors
Clinical hold/Recruitment or enrollment suspended
2-125 Years
NCI
Neoplasm
13-C-0152
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid Tumors
Completed Study; data analyses ongoing
2-29 Years
NCI
Malignant
13-C-0132
Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC Syndrome
Participants currently recruited/enrolled
8-70 Years
NCI
Peripheral
13-C-0119
Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
13-C-0105
Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Completed Study; data analyses ongoing
18-120 Years
NCI
Neoplasm
12-N-0095
Clinical and Molecular Manifestations of Neuromuscular and Neurogenetic Disorders of Childhood
Participants currently recruited/enrolled
0-100 Years
NINDS
Nerve
12-H-0064
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Participants currently recruited/enrolled
4-75 Years
NHLBI
Neoplasm
12-H-0035
A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p Deletion
No longer recruiting/follow-up only
18-125 Years
NHLBI
Neoplasm
12-C-0205
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
12-C-0118
A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy
No longer recruiting/follow-up only
18-100 Years
NCI
Neoplasm
12-C-0081
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
Neoplasm
12-C-0079
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
12-C-0066
Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
11-N-0211
Deep Brain Stimulation Surgery for Movement Disorders
Participants currently recruited/enrolled
18-99 Years
NINDS
Nerve
11-I-0007
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined Immunodeficiency
Participants currently recruited/enrolled
2-40 Years
NIAID
Peripheral
11-CC-0152
The Natural History of Liver Disease in a Cohort of Participants with Hepatitis B and/or Hepatitis C with or without HIV Infection
Completed Study; data analyses ongoing
18-99 Years
CC
Neoplasm
11-C-0255
Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome
Participants currently recruited/enrolled
0-125 Years
NCI
Neoplasm
11-C-0247
A Randomized Phase II Study of Tecemotide in Combination with Standard Androgen Deprivation Therapy and Radiation Therapy for untreated, intermediate and High Risk Prostate Cancer Patients
Completed Study; data analyses ongoing
18-100 Years
NCI
Neoplasm
11-C-0161
A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
No longer recruiting/follow-up only
2-18 Years
NCI
Nerve
11-C-0140
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
11-C-0061
Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
No longer recruiting/follow-up only
18-120 Years
NCI
Neoplasm
10-N-0009
Physiological Investigations of Movement Disorders
Completed Study; data analyses ongoing
18-125 Years
NINDS
Nerve
10-DK-0102
Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer
Participants currently recruited/enrolled
7-90 Years
NIDDK
Malignant
10-CC-0217
A Comparison of Methods for Assisting Needle Angle Selection During Image-Guided Tissue Biopsy
Completed Study; data analyses ongoing
18-125 Years
CC
Neoplasm
10-C-0201
Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells from Patients with DOCK8 Deficiency, LAD-1, and GATA2 Deficiency
Participants currently recruited/enrolled
18-40 Years
NCI
Peripheral
09-N-0039
A Phase I Study of the Intrathecal Administration of Resiniferatoxin for Treating Severe Refractory Pain Associated with Advanced Cancer
Participants currently recruited/enrolled
18-99 Years
NINDS
Nerve
09-H-0225
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia
No longer recruiting/follow-up only
2-100 Years
NHLBI
Peripheral
09-C-0139
A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
09-C-0053
Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Don
Enrolling by Invitation
1-125 Years
NCI
Neoplasm
08-H-0046
Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy
Completed Study; data analyses ongoing
4-75 Years
NHLBI
Peripheral
07-C-0100
Collection of Blood from Patients with Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Neoplasm
06-C-0213
Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
Participants currently recruited/enrolled
0-125 Years
NCI
Neoplasm
06-C-0014
Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies
Participants currently recruited/enrolled
2-125 Years
NCI
Malignant
05-H-0130
Long-Term Evaluation and Follow Up Care of Patients Treated with Allogeneic Stem Cell Transplants
Participants currently recruited/enrolled
7-80 Years
NHLBI
Peripheral
05-CC-0091
Electromagnetic Tracking of Devices During Interventional Procedures
Enrolling by Invitation
18-120 Years
CC
Neoplasm
04-N-0056
The Neural Immune Mechanisms and Genetic Influences on Chronic Pelvic Pain in Women with Endometriosis
Completed Study; data analyses ongoing
18-50 Years
NINDS
Nerve
04-I-0286
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Participants currently recruited/enrolled
1-100 Years
NIAID
Nerve
04-H-0012
Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples from Patients with Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members
Participants currently recruited/enrolled
2-100 Years
NHLBI
Neoplasm
04-C-0232
A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse
Completed Study; data analyses ongoing
18-125 Years
NCI
Neoplasm
04-C-0165
Data Collection, Clinical Care and Interventions in CCR, NCI
Enrolling by Invitation
0-120 Years
NCI
Neoplasm
03-H-0170
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia
No longer recruiting/follow-up only
2-80 Years
NHLBI
Peripheral
02-H-0250
A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1H
Completed Study; data analyses ongoing
18-100 Years
NHLBI
Peripheral
02-DK-N304
Diabetes Prevention Program Outcomes Study (DPPOS)
Participants currently recruited/enrolled
25-99 Years
NIDDK
Nerve
02-C-0159
Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts
Participants currently recruited/enrolled
2-125 Years
NCI
Neoplasm
02-C-0064
Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy
Enrolling by Invitation
18-125 Years
NCI
Peripheral
99-H-0050
Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases
Completed Study; data analyses ongoing
2-80 Years
NHLBI
Peripheral
99-C-0099
Examination of Clinical and Laboratory Abnormalities in Patients with Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
No longer recruiting/follow-up only
0-125 Years
NCI
Neoplasm
98-D-0145
Screening and Natural History of Patients with Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
Participants currently recruited/enrolled
0-100 Years
NIDCR
Nerve
97-CH-0076
A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders
Participants currently recruited/enrolled
3-70 Years
NICHD
Neoplasm
96-H-0049
Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections from Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation
Participants currently recruited/enrolled
18-60 Years
NHLBI
Peripheral
95-CH-0059
Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions
Completed Study; data analyses ongoing
3-70 Years
NICHD
Nerve
94-I-0073
Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes
Participants currently recruited/enrolled
18-70 Years
NIAID
Peripheral
94-HG-0105
An Exploratory Study of the Genetics, Pathophysiology, and Natural History of Autoinflammatory Diseases
Participants currently recruited/enrolled
0-115 Years
NHGRI
Nerve
93-I-0063
Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T Cells
Participants currently recruited/enrolled
0-99 Years
NIAID
Peripheral
92-I-0125
A Study of Viral Burden in Peripheral Blood Versus Lymphoid and Bone Marrow Tissue in HIV-Infected Individuals
Participants currently recruited/enrolled
18-125 Years
NIAID
Peripheral
91-I-0140
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood cells and/or Body Fluids in People Living With and Without HIV
Participants currently recruited/enrolled
18-120 Years
NIAID
Peripheral
89-C-0086
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Participants currently recruited/enrolled
2-125 Years
NCI
Malignant
78-C-0039
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
No longer recruiting/follow-up only
0-125 Years
NCI
Neoplasm